Bayer to make 'careful but aggressive' return to pharma M&A, CEO says

Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-quarter earnings call ...